Life Sciences
doggybone DNA: A Rapid Enzymatic GMP Starting Material for mRNA Production
In this GENwebinar, presenters Tom Adie, PhD, head of platform discovery, Touchlight and Scott Alderucci, director of process development, Curia, will…
Broadcast Date: September 27, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
Many biotech and pharmaceutical companies focused on mRNA manufacturing experience challenges associated with their plasmid DNA (pDNA) supply, including slow or delayed production and poor or inconsistent DNA quality, impacting their ability to meet timelines.
In this webinar, presenters Tom Adie, PhD, head of platform discovery, Touchlight and Scott Alderucci, director of process development, Curia, will address the evolving challenges of pDNA in mRNA manufacture, and discuss an alternative to pDNA—an enzymatic, antibiotic-free DNA vector called doggybone DNA (dbDNA). The webinar will outline how Touchlight and Curia are combining Touchlight’s dbDNA platform with Curia’s mRNA manufacturing capability to bring a rapid, reliable and high-quality solution to the market.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
Tom Adie, PhD
Head of Platform Discovery
Touchlight
Scott Alderucci
Director of Process Development
Curia
The post doggybone DNA: A Rapid Enzymatic GMP Starting Material for mRNA Production appeared first on GEN – Genetic Engineering and Biotechnology News.
Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….
